April 25, 2017

Biologics Summit Continues to Grow

Over 300 attendees address breakthroughs in translational immunology

Calabrese- Biologics Summit Continues to Grow

Healthcare providers from 10 countries and 33 states recently gathered in Cleveland for the seventh annual Biologic Therapies Summit and the Primary Vasculitides presymposium. Physicians, scientists and advanced practice providers from virtually every medical specialty and scientific field heard their colleagues on the leading edge of this work highlight the hopes and challenges of precision medicine for the nearly 50 million people in the U.S. with disorders of immunity.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“In 2005, we started the Summit to coincide with the opening of the R.J. Fasenmyer Center for Clinical Immunology and serve part of our threefold mission to educate other physicians, healthcare workers and the general public regarding immunologic diseases,” says Leonard H. Calabrese, DO, Director of the Center and the Summit. “What started out as a local meeting grew to regional, then national, and now is broadcast and simulcast internationally as one of the top meetings in the field.”

Presenters from the Department of Rheumatic and Immunologic Diseases at Cleveland Clinic included:

Highlighting the collaborative nature of the department’s work and the wide range of applications in biologic therapies, other Cleveland Clinic participants included:

Advertisement

Iain McInnes, PhD, gave the R.J. Fasenmyer Annual Lectureship, entitled “Cytokine Profiles in Health and Disease – What Can They Inform Us?” Dr. McInnes is Muirhead Professor of Medicine, ARUK Professor of Rheumatology and Director of the Institute of Infection Immunity and Inflammation at the University of Glasgow.

The summit’s growth illustrates the impact of biologics on the field. “I believe that biologics have changed rheumatology and the treatment of immune-mediated inflammatory disease fundamentally,” says Dr. Calabrese. “They’ve raised the bar, we are no longer satisfied with small outcomes… these great responses in patients improve quality of life, productivity and increase longevity.”

Related Articles

Medical illustration of hand with discolored fingers
February 27, 2024
Coexistence of Erythromelalgia and Raynaud’s Phenomenon

Treatment strategies require understanding of pathomechanisms

Squamous cell skin cancer
November 30, 2023
Skin Cancer Risk in Immunosuppressed Patients

Education, prevention strategies and monitoring serves this at-risk group

esophageal plaques
November 28, 2023
Esophageal Plaques and Systemic Sclerosis

Treatment for scleroderma can sometimes cause esophageal symptoms

Lupus clinic
November 24, 2023
Coordinated Care, Education and Research

Lupus Clinic providers collaborate to advance treatment and understanding

Skin lesions
November 15, 2023
Case Study: Joint Pain, Angioedema, Confusing Rash

Symptoms complement one another

Sjogren's Syndrome medical illustration
July 25, 2023
Case: Getting to the Root of Neuropathic Symptoms

Collaboration was key to identifying source of nerve condition

Middle-aged Black woman talks with doctor
July 21, 2023
Emerging Treatments for Systemic Lupus Erythematosus

A review of expanding options that hold new promise

20-RHE-2006260-Langford_VEXAS-syndrome-CQD-650×450 play
May 3, 2023
Case Study: Making the VEXAS Diagnosis (Video)

Patient’s symptoms included periorbital edema, fevers, weight loss

Ad